IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA CLARKSBURG DIVISION

IN RE: AFLIBERCEPT PATENT

LITIGATION

MDL No.: 1:24-md-3103-TSK

THIS DOCUMENT RELATES TO CASE NO. 1:23-cv-00089-TSK CASE NO. 1:24-cv-00053-TSK

STIPULATION AND ORDER DISMISSING ALL CLAIMS AND COUNTERCLAIMS, VACATING PRELIMINARY INJUNCTION PREVIOUSLY ISSUED BY THE COURT, AND RELEASING PRELIMINARY INJUNCTION BOND

Plaintiff Regeneron Pharmaceuticals, Inc. ("Regeneron") and Defendant Celltrion, Inc. ("Celltrion"), subject to the approval of the Court, hereby enter into the following Stipulation to dismiss without prejudice and release the preliminary injunction bond.

WHEREAS, Regeneron and Celltrion have reached an agreement that will resolve all issues between them without further litigation regarding Celltrion's 2 mg aflibercept product.

NOW THEREFORE Regeneron and Celltrion, by and through their respective undersigned counsel in this Action, and subject to the approval of the Court, stipulate and agree as follows:

- The Court's Order for Injunctive Relief Against Celltrion (24-md-3103, ECF No. 252), entered on July 10, 2024, is hereby vacated.
- 2. Pursuant to Rule 41(a)(1)(ii) of the Federal Rules of Civil Procedure, Regeneron's Case Nos. 1:23-cv-89 and 1:24-cv-53 against Celltrion (which was made a part of MDL No. 24-md-3103-TSK), including all claims and defenses asserted by

Regeneron against Celltrion and all counterclaims and defenses asserted by Celltrion against Regeneron, are hereby dismissed, without prejudice to the extent

specified in the parties' agreement.

3. All parties shall bear their own costs, disbursements, and attorneys' fees.

4. The Court's Order Establishing Security Under Federal Rule of Civil Procedure

65(c) [24-md-3103, ECF No. 272] is hereby vacated and the preliminary injunction

bond, Bond #CGB9428697 [24-md-3103, ECF No. 294], is hereby released to the

Sureties, Fidelity and Deposit Company of Maryland and Zurich American

Insurance Company.

5. The Court's Stipulated Protective Order [23-cv-00089, ECF No. 112] is modified

as follows: the prohibitions of sections 9(b) and 9(h) that terminate "one (1) year

after final termination of this Action" will instead terminate on September 29, 2026.

6. The Court's Stipulations To Amend Complaint & Set Deadline to Respond [24-

md-3103, ECF Nos. 423 and 424] are modified as follows: paragraph 4 of each

Order is vacated.

All pending motions in Case Nos 1:23-cv-89 and 1:24-cv-53 are hereby TERMINATED and the Clerk is DIRECTED to STRIKE Case Nos. 1:23-cv-89 and 1:24-cv-53 from the Court's active docket and to STRIKE Celltrion as a party in Case No. 1:24-md-03103.

SO ORDERED this 21st day of October, 2025

Hon. Thomas S. Kleeh, Chief Judge

Date: October 20, 2025

Of Counsel:

CAREY DOUGLAS KESSLER & RUBY, PLLC

Tom & Klul

David I. Berl (admitted *PHV*)

/s/ Steven R. Ruby

Ellen E. Oberwetter (admitted *PHV*) Thomas S. Fletcher (admitted *PHV*) Andrew V. Trask (admitted *PHV*) Teagan J. Gregory (admitted *PHV*) Shaun P. Mahaffy (admitted *PHV*) Kathryn S. Kayali (admitted *PHV*) Arthur J. Argall III (admitted *PHV*) Adam Pan (admitted *PHV*) Rhochelle Krawetz (admitted *PHV*) Jennalee Beazley (admitted *PHV*) WILLIAMS & CONNOLLY LLP 680 Maine Avenue, SW Washington, DC 20024 (202) 434-5000 dberl@wc.com eoberwetter@wc.com tfletcher@wc.com atrask@wc.com tgregory@wc.com smahaffy@wc.com kkayali@wc.com aargall@wc.com apan@wc.com rkrawetz@wc.com

jbeazley@wc.com

Steven R. Ruby (WVSB No. 10752)
David R. Pogue (WVSB No. 10806)
Raymond S. Franks II (WVSB No. 6523)
707 Virginia Street East
901 Chase Tower (25301)
P.O. Box 913
Charleston, West Virginia 25323
(304) 345-1234
sruby@cdkrlaw.com
drpogue@cdkrlaw.com

Attorneys for Plaintiff Regeneron Pharmaceuticals, Inc.

Elizabeth Stotland Weiswasser (admitted *PHV*)
PAUL, WEISS, RIFKIND, WHARTON & GARRISON
LLP
1285 Avenue of the Americas
New York, NY 10019
(212) 373-3000
eweiswasser@paulweiss.com

Christopher M. Pepe (admitted *PHV*)
Priyata Y. Patel (admitted *PHV*)
PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP
2001 K Street, NW
Washington, DC 20006
(202) 223-7300
cpepe@paulweiss.com
ppatel@paulweiss.com

Andrew E. Goldsmith (admitted *PHV*)
Jacob E. Hartman (admitted *PHV*)
Mary Charlotte Y. Carroll (admitted *PHV*)
Sven E. Henningson (admitted *PHV*)
KELLOGG, HANSEN, TODD, FIGEL &
FREDERICK, P.L.L.C.
1615 M Street, N.W., Suite 400
Washington, D.C. 20036
TEL: (202) 326-7900
agoldsmith@kellogghansen.com
eleo@kellogghansen.com
jhartman@kellogghansen.com
mcarroll@kellogghansen.com
shenningson@kellogghansen.com

Attorneys for Plaintiff Regeneron Pharmaceuticals, Inc.

Dated: October 20, 2025

/s/ Max C. Gottlieb

Michael B. Hissam (WVSB #11526)
Max C. Gottlieb (WVSB #13201)
Andrew C. Robey (WVSB #12806)
Carl W. Shaffer (WVSB #13260)
HISSAM FORMAN DONOVAN RITCHIE PLLC
P.O. Box 3983
Charleston, WV 25339
681-265-3802 office
304-982-8056 fax
mhissam@hfdrlaw.com
mgottlieb@hfdrlaw.com
cshaffer@hfdrlaw.com

OF COUNSEL:

GEMINI LAW LLP Robert Cerwinski Aviv Zalcenstein Michael Cottler Lora Green David Kim Brigid Morris Kyle Musgrove Cindy Chang 40 W 24th Street New York, NY 10010 (917) 915-8832

WILLKIE FARR & GALLAGHER LLP Michael W. Johnson Matt Freimuth Dan Constantinescu Ocean Lu 787 Seventh Avenue New York, NY 10019 (212) 728-8000

Attorneys for Defendant Celltrion, Inc.